Larimar Therapeutics Inc (LRMR NASDAQ) stock market data APIs
$2.2523
-0.07(-3.1%)
as of May 8, 2025
Larimar Therapeutics Inc Financial Data Overview
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
Prev. Close
2.2523
Open
2.1795
High
2.3067
Low
2.032
52 wk Range
1.61-11.2
Market Cap
172 M
Shares Outstanding
64 028 K
EPS
-0.46
Beta
0.869
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Larimar Therapeutics Inc data using free add-ons & libraries
Get Larimar Therapeutics Inc Fundamental Data
Larimar Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -105 018 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-07
- EPS/Forecast: -0.4091
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Larimar Therapeutics Inc News
New
Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results
FDA stated in written correspondence for a START pilot program meeting that it is open to considering skin FXN concentration as a reasonably likely surrogate endpoint in support of an accelerated appr...
Larimar Therapeutics to Present at the Leerink Partners Global Healthcare Conference
BALA CYNWYD, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare di...
Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich’s Ataxia
Adolescents receive a weight-based dose equivalent to the 50 mg adult dose Adolescents 12-17 years old who complete participation in the pharmacokinetic (PK) run-in study will be eligible to screen in...
Billionaire Steve Cohen and Insiders Are Buying These 10 Stocks
In this article, we will take a detailed look at theBillionaire Steve Cohen and Insiders Are Buying These 10 Stocks. For a quick overview of such stocks, read our article Billionaire Steve Cohen and I...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
